Weiankang Granule Dossier

A digestive-system granule dossier oriented to epigastric pain and standardized formulation communication.

Patent Overview

A digestive-system granule dossier oriented to epigastric pain and standardized formulation communication.

Indication: Chronic Gastritis Direction, Digestive System Common Disease Data Compilation, Traditional Chinese Medicine Granule Communication

Principle and Advantage

GastroHealth Granules are suitable to be regarded as a 'standardized granule asset in common digestive system diseases.' It targets high-frequency consultation scenarios rather than single-point rare diseases, with advantages in broad population coverage and clear dosage form expression.

Scientific Basis: Liver-Stomach Disharmony, Mixed Deficiency and Excess, Spleen and Stomach Regulation

  • Focus on common diseases with broad clinical demand.
  • The granule dosage form is well-defined, facilitating standardized documentation and subsequent translation into commercial products.
  • It can serve as an entry point in the digestive system asset portfolio.

Market Context

Market reference:Gastroscopy prevalence proxy: 42%–78%; Condition profile: High-frequency digestive complaint

  • The focus of communication in the common disease track is not mystery, but standardization and adherence.
  • Granule expression is more suitable for creating ready-made material packages and subsequent commercial discussions.
  • The digestive system direction can form a continuous asset chain with existing monographs and chapter content.

Proton pump inhibitors

Acid-suppression therapy · Common basic treatment pathways in managing chronic gastritis and related symptoms.

This asset is more suitable to be placed alongside common Western medicine pathways for complementary expression.

Bismuth agents

Gastric mucosa protection · Common pathways in gastric mucosal protection and related digestive system treatments.

The package insert is based on existing symptomatic treatments.

Antibiotic regimens

Anti-infective treatment · Treatment related to gastric infections is part of the existing standard pathway.

This is to clarify that the current regimen is not blank but rather follows an established Western medicine pathway.

Related Books

Cooperation

Suitable for asset documentation in the digestive system field, technical discussions on granule formulations, and preliminary exchanges for subsequent product development.

Indication · March 18, 2026

合规提示

This page is for academic exchange and collaboration reference and does not constitute medical advice, product marketing, or efficacy claims.